Detalles del recurso
Pertenece a:
PubMed Central (PMC3 - NLM DTD)
Descripción: Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype, patients with DLBCL still exhibit substantially different survival rates. In MCL, a mature B-cell lymphoma, the addition of rituximab to conventional chemotherapy regimens has increased response rates, but not survival. Burkitt lymphoma, the most aggressive BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there is a need for more effective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in this paper.
Autor(es): Foon, Kenneth A. - Takeshita, Kenichi - Zinzani, Pier L. -
Id.: 55223208
Idioma:
inglés
-
Versión: 1.0
Estado: Final
Palabras clave: Review Article -
Tipo de recurso:
Text
-
Tipo de Interactividad: Expositivo
Nivel de Interactividad: muy bajo
Audiencia:
Estudiante
- Profesor
- Autor
-
Estructura: Atomic
Coste: no
Copyright: sí
Requerimientos técnicos: Browser: Any -
Fecha de contribución: 27-abr-2012
Contacto:
Localización:
